Literature DB >> 152611

Dinitrochlorobenzene therapy for alopecia areata.

R Happle, K Cebulla, K Echternacht-Happle.   

Abstract

Ninety patients with alopecia areata were treated with weekly applications to one side of the head of dinitrochlorobenzene (DNCB) dissolved in acetone, the other side of the head serving as control region. In 80 patients (89%) hair regrew either exclusively on the treated side, or considerably faster and denser on this side. The difference was noted, in the majority of cases, within eight weeks. The initial response, however, could not be maintained in all of these patients. Persistent response was observed in 72 patients (80%). Peribulbar round cell infiltrates were found to be more constant and denser on the treated side, suggesting that topically applied DNCB affects the peribulbar infiltrate present in alopecia areata. Possibly, the therapeutic result is due to altered local immunoregulation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 152611

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  Dinitrochlorobenzene: influence on the cytochrome P-450 system and mutagenic effects.

Authors:  J Kratka; G Goerz; W Vizethum; R Strobel
Journal:  Arch Dermatol Res       Date:  1979-11       Impact factor: 3.017

2.  Immunotherapy of alopecia areata.

Authors:  D Van Neste; M De Bruyère; F Breuillard
Journal:  Arch Dermatol Res       Date:  1979-11       Impact factor: 3.017

3.  Vitiligo after diphencyprone for alopecia areata.

Authors:  Mario Cezar Pires; João Mauricio Martins; F Montealegre; Flávia Romero Gatti
Journal:  Dermatol Res Pract       Date:  2010-05-11

4.  Antigenic competition as a therapeutic concept for alopecia areata.

Authors:  R Happle
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

5.  Mutagenic and cell transforming activities of 1-chlor-2,4-dinitrobenzene (DNCB) and squaric-acid-dibutylester (SADBE).

Authors:  R Strobel; G Röhrborn
Journal:  Arch Toxicol       Date:  1980-10       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.